Interestingly, the downregulation of DNASE1L3 expression was commonly seen across various cancer types such as colorectal cancer, lung cancer, nasopharyngeal carcinoma, and head and neck squamous cell carcinoma [39], supporting the potential decline of DNASE1L3 in patients with cancers. This evidence concerns the gene DNASE1L3 and lung cancer.